医薬品の立場から : マイトマイシンC(日本環境変異原学会第32回大会シンポジウム3「リスクアセスメントの現状と展望 : レギュラトリーサイエンスへの係わり」)

概要

論文の詳細を見る
A quantitative genetic risk assessment has been recognized as one of the goals of the research of environmental mutagens. To establish the genetic risk assessment as a practice routinely applicable to daily tasks, a collaborative study was carried out from 1996 to 1999 in the Mammalian Mutagenesis Study Group. Mitomycin C was selected as a model compound and its genetic risk was quantitatively assessed for autosomal dominant and X linked genetic diseases. In this paper, outcomes of the study are presented together with the recent progress in a genetic risk assessment on radiation.
日本環境変異原学会の論文
2004-09-30